ADHD medication timing linked to differences in children’s brain iron

Children who began stimulant treatment by age eight had higher iron levels in several dopamine-linked brain regions than those who started later, although the study cannot show that medication caused the differences.

Children with attention deficit hyperactivity disorder may not all respond to stimulant treatment in the same way, and the age at which medication begins could matter for the brain’s iron balance. A study in Brain Research found that youngsters who started psychostimulants by age eight showed higher iron concentrations in several dopamine-linked brain regions than those who began at nine or older, a pattern that adds a new layer to earlier work suggesting that medication can influence brain iron levels over time.

The findings build on previous neuroimaging research showing that medication-naive children with ADHD often have lower brain iron than neurotypical peers, while those treated with stimulants may look more similar to controls. A systematic review indexed by PubMed reported that reduced iron levels appear to be a recurring feature in unmedicated children and adolescents with ADHD, and that psychostimulant use may help normalise those measures. Earlier imaging studies in Radiology and NeuroImage: Clinical also found that iron deficits were most evident in children who had never taken stimulants, with medicated groups showing levels closer to those of children without ADHD.

In the new longitudinal analysis, researchers followed children drawn from the Oregon ADHD-1000 dataset and compared MRI scans taken at the start of the study and again two years later. After adjusting for age, sex and intelligence quotient, they found no meaningful group differences in most dopamine-rich regions, including the substantia nigra and thalamus, but they did identify lower iron in the globus pallidus among children with ADHD. Treatment length itself was not strongly linked to brain iron, aside from a very small thalamic association that the authors said was unlikely to have practical significance.

The stronger signal came from treatment timing. Children who had begun stimulant medication earlier in childhood, at age eight or younger, had higher iron content in the thalamus, caudate nucleus, putamen and globus pallidus than those who started later. The authors suggested that these results may reflect a sensitive developmental window, when the dopamine system is still changing rapidly. But they also cautioned that the study was small, relied on parent reports for treatment history and did not include pre-treatment brain scans, so the results show an association rather than proof that medication caused the differences. Larger prospective studies that follow children from before treatment starts, the researchers said, will be needed to determine whether the pattern persists into adolescence and adulthood.